Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02649868 | LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of… | N/A | terminated | Jan 8, 2016 | National Institutes of Health Clinical Center (CC) | unavailability of study device | Other (stated, no rule matched) |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | Phase 2 | terminated | Aug 18, 2021 | CSPC Ouyi Pharmaceutical Co., Ltd. | Internal strategy change. Not related to safety concerns. | Safety / toxicity |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT05690035 | Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer | Phase 2 | withdrawn | Jan 19, 2023 | Sun Yat-sen University | Due to slow patient recruiting. No patients were enrolled 12 months after study initiation. | Enrollment / accrual |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT03631641 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History… | Phase 2 | terminated | Aug 15, 2018 | John Hays | Sponsor decision | Sponsor / business decision |
| NCT01034670 | Advanced Gastrointestinal Endoscopic Imaging | N/A | terminated | Dec 17, 2009 | Stanford University | Change in personnel and cessation of funding | Funding |
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | Phase 2 | terminated | Oct 20, 2015 | Wake Forest University Health Sciences | Funder terminated. | Other (stated, no rule matched) |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | Phase 1 | withdrawn | Apr 6, 2021 | Stanford University | Business Decision | Sponsor / business decision |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05553795 | Drainless Robot-assisted Minimally Invasive Esophagectomy(RESPECT) | N/A | terminated | Sep 23, 2022 | Technische Universität Dresden | Following a safety analysis and assessment of the complications encountered by external experts, it… | Safety / toxicity |
| NCT03492164 | In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer | Early Phase 1 | terminated | Apr 10, 2018 | Abramson Cancer Center at Penn Medicine | Early analysis of images after 6 patients showed no activity of the radiotracer in this patient… | Other (stated, no rule matched) |
| NCT04315883 | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | — | terminated | Mar 20, 2020 | Nemours Children's Clinic | PI left organization and discontinued study | Investigator |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | N/A | withdrawn | Oct 14, 2020 | Medical University of Graz | Covid19 Pandemia | COVID-19 / pandemic |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With… | Phase 1 / Phase 2 | terminated | May 2, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04843306 | Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients | N/A | terminated | Apr 13, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Technical difficulties that were not able to be resolved. | Other (stated, no rule matched) |
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable… | Phase 2 | terminated | Sep 9, 2020 | Aiwu Ruth He, MD | Due to slow accrual. | Enrollment / accrual |
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated… | Phase 2 | terminated | Feb 15, 2019 | Shadia Jalal, MD | Due to slow accruals | Enrollment / accrual |
| NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Sep 15, 2016 | University of Texas Southwestern Medical Center | The study was terminated due to futility and lack of future funding | Efficacy / futility |
| NCT05609656 | Electroporation and Immunotherapy in Metastatic Colorectal Cancer(ELI) | Phase 2 | terminated | Nov 8, 2022 | Ismail Gögenur | The study was terminated on the basis on an evaluation of the efficacy and safety of the 4 included… | Safety / toxicity |
| NCT05116917 | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.(INFLUENCE) | Phase 2 | terminated | Nov 11, 2021 | Herlev Hospital | Based on the precpecified interim analysis the predictive probability was below 10% for the… | Efficacy / futility |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects…(SLC-0111-17-01) | Phase 1 / Phase 2 | terminated | Mar 1, 2018 | British Columbia Cancer Agency | Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the… | Enrollment / accrual |
| NCT03730948 | DC Vaccine in Colorectal Cancer | Phase 1 | terminated | Nov 5, 2018 | University of Pennsylvania | Lack of enrollment | Enrollment / accrual |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating… | Phase 1 | terminated | Oct 3, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04698915 | Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer | Phase 2 | terminated | Jan 7, 2021 | Galera Therapeutics, Inc. | Futility Analysis | Efficacy / futility |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | N/A | terminated | Jan 22, 2021 | Centre Hospitalier Henri Duffaut - Avignon | Heart rate measurement error | Other (stated, no rule matched) |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2… | Phase 3 | terminated | Dec 12, 2018 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development… | Safety / toxicity |
| NCT05359042 | Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers | N/A | withdrawn | May 3, 2022 | University of California, San Francisco | Logistical constraints | Other (stated, no rule matched) |
| NCT04090463 | IORT on Borderline Resectable Pancreatic Cancer(PancFORT) | Phase 2 | suspended | Sep 16, 2019 | Universita di Verona | Logistic and financial reasons | Funding |
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of… | Phase 1 | terminated | Sep 12, 2019 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a… | Phase 2 | terminated | May 15, 2020 | Academic and Community Cancer Research United | Slow accrual | Enrollment / accrual |
| NCT04073615 | A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) | Phase 1 | terminated | Aug 29, 2019 | Elevar Therapeutics | Phase 2 portion of the study was not performed due to redirection of the rivoceranib development… | Other (stated, no rule matched) |
| NCT05354856 | The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer. | Phase 4 | terminated | May 2, 2022 | Rigshospitalet, Denmark | recruiting issues | Enrollment / accrual |
| NCT05648006 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | Phase 2 | terminated | Dec 13, 2022 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With… | Phase 2 | withdrawn | Jun 12, 2023 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT00838578 | Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | Phase 1 / Phase 2 | terminated | Feb 6, 2009 | Kyowa Kirin Co., Ltd. | Per protocol, the study was terminated based on interim analysis results | Efficacy / futility |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid…(MYCure) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Peptomyc S.L. | Phase 1completed; sponsor decided to change strategy to a combination study | Sponsor / business decision |
| NCT02452970 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration…(EPIC) | Phase 2 | terminated | May 25, 2015 | EpicentRx, Inc. | Poor enrollment and adverse event experiences in the limited population | Safety / toxicity |
| NCT03402477 | "Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal…(NORWAIT) | — | terminated | Jan 18, 2018 | Helse Stavanger HF | Suspicion of adverse events | Safety / toxicity |
| NCT03848182 | Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer | Phase 2 | terminated | Feb 20, 2019 | Albert Einstein College of Medicine | Slow accrual | Enrollment / accrual |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | N/A | terminated | Feb 1, 2021 | Milton S. Hershey Medical Center | Difficulty enrolling and we lost exercise specialist | Enrollment / accrual |
| NCT06371716 | Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions | N/A | terminated | Apr 17, 2024 | IRCCS San Raffaele | resectable pancreatic adenocarcinoma and neuroendocrine pancreatic neoplasms are difficult to be… | Enrollment / accrual |
| NCT03558724 | Fluorescence Endoscopy of Esophageal Carcinoma(ORCA) | Phase 1 | terminated | Jun 15, 2018 | University Medical Center Groningen | Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was… | Other (stated, no rule matched) |
| NCT04272268 | Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce…(Hi-FLO) | — | withdrawn | Feb 17, 2020 | University Hospitals of North Midlands NHS Trust | Covid-19 | COVID-19 / pandemic |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05356585 | Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal… | — | withdrawn | May 2, 2022 | Case Comprehensive Cancer Center | Sponsor already published research that was to be obtained from this study. | Other (stated, no rule matched) |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in…(FIDES-03) | Phase 1 / Phase 2 | terminated | Oct 27, 2020 | Basilea Pharmaceutica | Terminated prematurely for administrative reasons not related to patient safety. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 11, 2024source: clinicaltrials